Telitacicept Receives Two NMPA Approvals in China, Including First-Ever for Sjögren's Disease
VOR has more than doubled off its 52-week low of $3.626.
Summary
Vor Biopharma announced that its collaborator RemeGen received two NMPA approvals in China for telitacicept: one for Sjögren's disease (the first-ever global approval for this indication) and another for IgA nephropathy. These approvals validate the drug's potential and support Vor Bio's global development efforts.
Key Events · Product Development and Regulatory · VOR
-
NMPA Approval for Sjögren's Disease
Telitacicept received approval from China's NMPA for Sjögren's disease (SjD), marking the first-ever regulatory approval for this indication globally and the first approved therapy for SjD in China.
-
NMPA Conditional Approval for IgA Nephropathy
Telitacicept also received conditional approval from China's NMPA for IgA nephropathy (IgAN), becoming the first and only approved BAFF/APRIL-targeting therapy for this condition.
-
Validation for Global Development
These approvals in China, based on positive Phase 3 data, significantly validate telitacicept's mechanism of action and clinical efficacy, supporting Vor Biopharma's ongoing global Phase 3 trials for Sjögren's disease and generalized myasthenia gravis.
-
Fifth Indication for Telitacicept
Sjögren's disease marks the fifth indication approval for telitacicept in China, further demonstrating its broad potential across autoimmune diseases.
Analysis · VOR · Life Sciences
These NMPA approvals in China for telitacicept, particularly the first-ever regulatory approval for Sjögren's disease globally, provide significant validation for Vor Biopharma's lead asset. While RemeGen holds commercial rights in China, these milestones de-risk telitacicept and strengthen the clinical evidence supporting Vor Bio's ongoing global Phase 3 trials for Sjögren's disease and generalized myasthenia gravis. This positive news is crucial for a clinical-stage biotech company that recently reported substantial losses and raised capital to extend its runway.
At the time of this filing, VOR was trading at $13.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $720.1M. The 52-week trading range was $3.63 to $65.80. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.